Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2017-06-29 Regulatory Filings
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings
2017-06-29 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on a private placement transaction involving the sale of common stock and warrants, details of warrant repricing and exercises, and the agency agreement with the placement agent. There are no financial statements or comprehensive financial performance data presented, nor is this an annual or quarterly report. The document is primarily an update on capital raising activities and related agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (9544 characters) is sufficient to contain substantive information, not just an announcement or a brief notice, supporting this classification.
2017-06-26 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 21, 2017, by TapImmune Inc. It details a private placement transaction involving the sale of common stock and warrants, including subscription agreements, warrant repricings, and agency agreements. The content focuses on financing activities, specifically a private placement under Rule 506 of Regulation D, proceeds usage, and related agreements. There are no financial statements or comprehensive financial performance data typical of annual or quarterly reports. The document is not a report publication announcement or certification but a current report on material events. Therefore, the filing best fits the category of Capital/Financing Update (CAP).
2017-06-22 English
FORM 10-Q
Interim / Quarterly Report Q1 2017
2017-05-05 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 27, 2017, by TapImmune Inc. The key content is the announcement of a change in management: the resignation of Dr. John Bonfiglio as President, COO, and director, and the appointment of Dr. Glynn Wilson as President. It also mentions a reduction in the board size. The document includes a press release attached as an exhibit about the change in management and board of directors. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The primary focus is on management changes, which fits the category of Board/Management Information (MANG). The document length is about 4049 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the correct classification is MANG with high confidence.
2017-04-28 English
FORM 10-K
Annual Report FY 2016
2017-03-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.